The Goals of the Tissue Acquisition, Prcoessing and Pathology Core are: A. Review and analyze pathologic specimens from clinical trial patients (with Project 1), including expression of mesothelin levels and potentially other tumor antigens. B. Process and archive clinical specimens from ongoing and planned clinical trials (with Project 1). C Perform assays for Interferon-alpha, anti-adenoviral neutralizing antibodies, serum mesothelin, and antitumor antibodies (with Project 1) D. Tissue acquisition (with Projects 1, 2 and 3). E. Establish stable cell lines from tumors derived from clinical trial subjects and other surgical patients (with Projects 1, 2, and 3). F. Assist in immunohistochemical analyses Dr. Michael Kalos will be the Director of the TAPP Core due to the unfortunate death of Dr. Carroll. Dr. Leslie Litzky, a Board-Certified Anatomic Pathologist, will focus on goal A and continue in her previous role as the designated reference pathologist for confirmation of diagnosis prior to patient enrollment in clinical trials and review of mesothelin or other antigen expression on tumor samples. Dr. Steven Albelda who has the expertise needed to perform revised Goals C (previously established serological assays) and E (cell line establishment) will assist in this core.

Public Health Relevance

The TAPP core will support all 3 projects by providing important sen/ices including review of pathological specimens, specimen handling, biomarker assays, tissue acquistion, and immunohistochemical studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-B)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Maus, Marcela V; Fraietta, Joseph A; Levine, Bruce L et al. (2014) Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 32:189-225
Singh, Nathan; Liu, Xiaojun; Hulitt, Jessica et al. (2014) Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2:1059-70
Wang, Liang-Chuan S; Lo, Albert; Scholler, John et al. (2014) Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2:154-66
Barrett, David M; Singh, Nathan; Liu, Xiaojun et al. (2014) Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16:619-30
Moon, Edmund K; Wang, Liang-Chuan; Dolfi, Douglas V et al. (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20:4262-73
Beatty, Gregory L; Haas, Andrew R; Maus, Marcela V et al. (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112-20
Vonderheide, Robert H; June, Carl H (2014) Engineering T cells for cancer: our synthetic future. Immunol Rev 257:7-13
Fridlender, Z G; Jassar, A; Mishalian, I et al. (2013) Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer 108:1288-97
Baek, Kwan-Hyuck; Bhang, Dongha; Zaslavsky, Alexander et al. (2013) Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest 123:4375-89
Quatromoni, Jon G; Suzuki, Eiji; Okusanya, Olugbenga et al. (2013) The timing of TGF-* inhibition affects the generation of antigen-specific CD8+ T cells. BMC Immunol 14:30

Showing the most recent 10 out of 66 publications